Evaluating Aganirsen Eye Drops to Reduce the Number of Aflibercept Injections in Wet Age-Related Macular Degeneration Patients.

Prior treatment

• Who has received topical corticosteroids or topical non-steroidal anti-inflammatory drugs in the study eye within the past 28 days

Other illness

• Who has a retinal disease other than wAMD in the study eye
• Who has active, suspected or trace of recent ocular, periocular or intraocular infection or inflammation
• Who has a recent history (within the past 6 months) of myocardial infarction, stroke, transient ischemic attack, acute congestive heart failure or any acute coronary event
• Who is deprived of liberty or under psychiatric care without their consent,

Other

• Who has significant ocular media opacities in the study eye that might interfere with BCVA assessment, OCT imaging or safety assessment

• Participant aged ≥ 50 and ≤ 89 years old
• With a documented diagnosis of wAMD in the study eye
• Who received at least one intravitreal injection, in the study eye, within 48 months after diagnosis
• Currently treated with intravitreal aflibercept 8 mg according to a T&E dosing regimen, in the study eye
• Absence of retinal fluid (i.e., no IRF and SRF), in the study eye, under the current intravitreal aflibercept treatment interval
• With BCVA ≥ 1/10 in the study eye
• Who reports being able to self-administer eye drops twice daily for 9 months or who reports having a caregiver available and able to administer him/her eye drops twice daily for 9 months
• Who had experienced an unsuccessful extension of treatment (presence of fluid (i.e., presence of IRF or SRF)), following intravitreal aflibercept 8 mg according to a T&E dosing regimen, in the study eye, for at least 1 of the last 3 injections administered